The role of IL-21 in immunity and cancer

Cancer Letters

Volumn 358, Issue 2, 2015, Pages 107-114

  Davis, Matthew R ^a   Zhu, Ziwen ^b   Hansen, Dwayne M ^a   Bai, Qian ^b   Fang, Yujiang ^a,b  

^a Des Moines University College of Osteopathic Medicine   (United States)

^b University of Missouri   (United States)

Author keywords

Cancer; IL 21; Immune response

Indexed keywords

INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; RADIOSENSITIZING AGENT; INTERLEUKIN DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; B10 CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITE; EPITHELIUM CELL; HELPER CELL; HUMAN; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE FUNCTION; MACROPHAGE; MAST CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PLASMA CELL; PLEIOTROPY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SIGNAL TRANSDUCTION; TH17 CELL; ANIMAL; ANTIBODY PRODUCTION; APOPTOSIS; CELL COMMUNICATION; CYTOLOGY; GENE EXPRESSION; GENETICS; GERMINAL CENTER; IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIOTHERAPY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODY FORMATION; APOPTOSIS; B-LYMPHOCYTES; CELL COMMUNICATION; CELL DIFFERENTIATION; GENE EXPRESSION; GERMINAL CENTER; HUMANS; IMMUNITY; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKINS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RECEPTORS, INTERLEUKIN-21; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84921609249     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.047     Document Type: Review

References (91)

1. Spolski R., Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol 2008, 26:57-79.
2. Spolski R., Leonard W.J. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr. Opin. Immunol 2008, 20:295-301.
3. Schluns K.S., Lefrançois L. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol 2003, 3:269-279.
4. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol 2012, 12:180-190.
5. Schluns K.S., Kieper W.C., Jameson S.C., Lefrançois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol 2000, 1:426-432.
6. Tan J.T., Dudl E., LeRoy E., Murray R., Sprent J., Weinberg K.I., et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. PNAS 2001, 98:8732-8737.
7. Tan J.T., Ernst B., Kieper W.C., LeRoy E., Sprent J., Surh C.D. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med 2002, 195:1523-1532.
8. Judge A.D., Zhang X., Fujii H., Surh C.D., Sprent J. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8+ T cells. J. Exp. Med 2002, 196:935-946.
9. Noguchi M., Nakamura Y., Russell S.M., Ziegler S.F., Tsang M., Cao X., et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 1993, 262:1877-1880.
10. Davis I.D., Skak K., Smyth M.J., Kristjansen P.E., Miller D.M., Sivakumar P.V. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin. Cancer Res 2007, 13:6926-6932.
11. Zeng R., Spolski R., Casas E., Zhu W., Levy D.E., Leonard W.J. The molecular basis of IL-21-mediated proliferation. Blood 2007, 109:4135-4142.
12. Wang X., Rickert M., Garcia K.C. Structure of the quaternary complex of interleukin-2 with its α, ß, and γc receptors. Science 2005, 310:1159-1163.
13. Burkett P.R., Koka R., Chien M., Chai S., Boone D.L., Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Rα and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med 2004, 200:825-834.
14. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., et al. Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol 2001, 167:1-5.
15. Kim J.E., Patel M., Ruzevick J., Jackson C.M., Lim M. STAT3 Activation in glioblastoma: biochemical and therapeutic implications. Cancers 2014, 6:376-395.
16. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res 2002, 8:945-954.
17. Burke W.M., Jin X., Lin H.-J., Huang M., Liu R., Reynolds R.K., et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001, 20:7925-7934.
18. Corvinus F.M., Orth C., Moriggl R., Tsareva S.A., Wagner S., Pfitzner E.B., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555.
19. Rahaman S.O., Harbor P.C., Chernova O., Barnett G.H., Vogelbaum M.A., Haque S.J. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413.
20. Gunewardene M.S., Subach F.V., Gould T.J., Penoncello G.P., Gudheti M.V., Verkhusha V.V., et al. Superresolution imaging of multiple fluorescent proteins with highly overlapping emission spectra in living cells. Biophys. J. 2011, 101:1522-1528.
21. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
22. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2005, 25:1195-1204.
23. Berglund L.J., Avery D.T., Ma C.S., Moens L., Deenick E.K., Bustamante J., et al. IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood 2013, 122:3940-3950.
24. Linterman M.A., Beaton L., Yu D., Ramiscal R.R., Srivastava M., Hogan J.J., et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med 2010, 207:353-363.
25. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
26. Parrish-Novak J., Foster D.C., Holly R.D., Clegg C.H. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukoc. Biol 2002, 72:856-863.
27. Santegoets S.J., Turksma A.W., Powell D.J., Hooijberg E., de Gruijl T.D. IL-21 in cancer immunotherapy: at the right place at the right time. Oncoimmunology 2013, 2.
28. Eto D., Lao C., DiToro D., Barnett B., Escobar T.C., Kageyama R., et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS ONE 2011, 6. e17739.
29. Liu S.M., King C. IL-21-producing Th cells in immunity and autoimmunity. J. Immunol 2013, 191:3501-3506.
30. Pelletier M., Girard D. Differential effects of IL-15 and IL-21 in myeloid (CD11b+) and lymphoid (CD11b-) bone marrow cells. J. Immunol 2006, 177:100-108.
31. Pesce J., Kaviratne M., Ramalingam T.R., Thompson R.W., Urban J.F., Cheever A.W., et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest 2006, 116:2044-2055.
32. Wu Z., Kim H.-P., Xue H.-H., Liu H., Zhao K., Leonard W.J. Interleukin-21 receptor gene induction in human T cells is mediated by T-cell receptor-induced Sp1 activity. Mol. Cell. Biol 2005, 25:9741-9752.
33. Søndergaard H., Skak K. IL-21: roles in immunopathology and cancer therapy. Tissue Antigens 2009, 74:467-479.
34. Leonard W.J., Zeng R., Spolski R. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J. Leukoc. Biol 2008, 84:348-356.
35. Tangye S.G., Ma C.S., Brink R., Deenick E.K. The good, the bad and the ugly [mdash] TFH cells in human health and disease. Nat. Rev. Immunol 2013, 13:412-426.
36. Bryant V.L., Ma C.S., Avery D.T., Li Y., Good K.L., Corcoran L.M., et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J. Immunol 2007, 179:8180-8190.
37. Ettinger R., Sims G.P., Fairhurst A.-M., Robbins R., da Silva Y.S., Spolski R., et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol 2005, 175:7867-7879.
38. Jin H., Carrio R., Yu A., Malek T.R. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol 2004, 173:657-665.
39. Mehta D.S., Wurster A.L., Whitters M.J., Young D.A., Collins M., Grusby M.J. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol 2003, 170:4111-4118.
40. Avery D.T., Bryant V.L., Ma C.S., de Waal Malefyt R., Tangye S.G. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J. Immunol 2008, 181:1767-1779.
41. Brenne A.-T., Ro T.B., Waage A., Sundan A., Borset M., Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002, 99:3756-3762.
42. Zotos D., Coquet J.M., Zhang Y., Light A., D'Costa K., Kallies A., et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J. Exp. Med 2010, 207:365-378.
43. Ozaki K., Spolski R., Ettinger R., Kim H.-P., Wang G., Qi C.-F., et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol 2004, 173:5361-5371.
44. Avery D.T., Deenick E.K., Ma C.S., Suryani S., Simpson N., Chew G.Y., et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med 2010, 207:155-171.
45. Pène J., Gauchat J.-F., Lécart S., Drouet E., Guglielmi P., Boulay V., et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol 2004, 172:5154-5157.
46. Banchereau J., Rousset F. Human B lymphocytes: phenotype, proliferation, and differentiation. Adv. Immunol 1992, 52:125-262.
47. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559-569.
48. Harada M., Magara-Koyanagi K., Watarai H., Nagata Y., Ishii Y., Kojo S., et al. IL-21-induced Bε cell apoptosis mediated by natural killer T cells suppresses IgE responses. J. Exp. Med 2006, 203:2929-2937.
49. Kishida T., Hiromura Y., Shin-Ya M., Asada H., Kuriyama H., Sugai M., et al. IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. J. Immunol 2007, 179:8554-8561.
50. Kuchen S., Robbins R., Sims G.P., Sheng C., Phillips T.M., Lipsky P.E., et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J. Immunol 2007, 179:5886-5896.
51. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol 2007, 178:6730-6733.
52. Santegoets S.J., Turksma A.W., Suhoski M.M., Stam A.G., Albelda S.M., Hooijberg E., et al. IL-21 promotes the expansion of CD27 CD28 tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J. Transl. Med 2013, 11:37.
53. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J. Immunol 2004, 172:2048-2058.
54. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012, 7. e30264.
55. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003, 63:9016-9022.
56. Ugai S.-I., Shimozato O., Yu L., Wang Y.-Q., Kawamura K., Yamamoto H., et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and-independent antitumor effects. Cancer Gene Ther 2003, 10:771-778.
57. Smyth M.J., Hayakawa Y., Cretney E., Zerafa N., Sivakumar P., Yagita H., et al. IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J. Immunol 2006, 176:6347-6355.
58. Takeda K., Yamaguchi N., Akiba H., Kojima Y., Hayakawa Y., Tanner J.E., et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med 2004, 199:437-448.
59. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., Carson W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol 2006, 177:120-129.
60. Di Carlo E., Comes A., Orengo A.M., Rosso O., Meazza R., Musiani P., et al. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol 2004, 172:1540-1547.
61. Hinrichs C.S., Spolski R., Paulos C.M., Gattinoni L., Kerstann K.W., Palmer D.C., et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111:5326-5333.
62. Moroz A., Eppolito C., Li Q., Tao J., Clegg C.H., Shrikant P.A. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol 2004, 173:900-909.
63. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med 2005, 201:139-148.
64. Li Y., Yee C. IL-21-mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 2008, 111:229-235.
65. Søndergaard H., Frederiksen K.S., Thygesen P., Galsgaard E.D., Skak K., Kristjansen P.E., et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol. Immunother 2007, 56:1417-1428.
66. Smyth M.J., Crowe N.Y., Pellicci D.G., Kyparissoudis K., Kelly J.M., Takeda K., et al. Sequential production of interferon-γ by NK1. 1 + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002, 99:1259-1266.
67. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med 2005, 201:1973-1985.
68. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J. Immunol 2014, 192:5451-5458.
69. Shablak A., Gilham D.E., Hawkins R.E., Elkord E. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opin. Pharmacother 2014, 1-11.
70. Wong M.K., Kaufman H.L., Daniels G.A., McDermott D.F., Aung S., Lowder J.N., et al. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J. Immunother. Cancer 2014, 2:20.
71. Barker C.A., Postow M.A. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int. J. Radiat. Oncol. Biol. Phys 2014, 88:986-997.
72. Kammula U.S., White D.E., Rosenberg S.A. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998, 83:797-805.
73. Schwartzentruber D.J. Guidelines for the safe administration of high-dose interleukin-2. J. Immunother 2001, 24:287-293.
74. Chow S., Cove-Smith L., Schmitt M., Hawkins R. High-dose interleukin 2-induced myocarditis: can myocardial damage reversibility be assessed by cardiac MRI?. J. Immunother 2014, 37:304-308.
75. Petrella T.M., Tozer R., Belanger K., Savage K.J., Wong R., Smylie M., et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J. Clin. Oncol 2012, 30:3396-3401.
76. Stolfi C., Pallone F., Macdonald T.T., Monteleone G. Interleukin-21 in cancer immunotherapy: friend or foe?. Oncoimmunology 2012, 1(3):351-354.
77. Monteleone G., Pallone F., Macdonald T.T. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytok. Growth Fac. Rev 2009, 20:185-191.
78. Publicover J., Goodsell A., Nishimura S., Vilarinho S., Wang Z.-E., Avanesyan L., et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J. Clin. Invest 2011, 121:1154-1162.
79. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol 2006, 45:529-538.
80. Kim C.-M., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
81. Gattinoni L., Klebanoff C.A., Restifo N.P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 2012, 12:671-684.
82. Yang S., Ji Y., Gattinoni L., Zhang L., Yu Z., Restifo N.P., et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother 2013, 62:727-736.
83. Davis I.D., Skrumsager B.K., Cebon J., Nicholaou T., Barlow J.W., Moller N.P.H., et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res 2007, 13:3630-3636.
84. Thompson J.A., Curti B.D., Redman B.G., Bhatia S., Weber J.S., Agarwala S.S., et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol 2008, 26:2034-2039.
85. Steele N., Anthony A., Saunders M., Esmarck B., Ehrnrooth E., Kristjansen P., et al. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br. J. Cancer 2012, 106:793-798.
86. Hashmi M.H., Van Veldhuizen P.J. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin. Biol. Ther 2010, 10:807-817.
87. Liu S., Lizée G., Lou Y., Liu C., Overwijk W.W., Wang G., et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int. Immunol 2007, 19:1213-1221.
88. Alves N.L., Arosa F.A., van Lier R.A. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J. Immunol 2005, 175:755-762.
89. Strengell M., Matikainen S., Sirén J., Lehtonen A., Foster D., Julkunen I., et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol 2003, 170:5464-5469.
90. Zhang Y., Wang J., Ren M., Li M., Chen D., Chen J., et al. Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice. J. Ovar. Res 2014, 7.
91. Castermans K., Tabruyn S.P., Zeng R., van Beijnum J.R., Eppolito C., Leonard W.J., et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood 2008, 112:4940-4947.